Crystal Structure of BACE with amino thiazine inhibitor LY2886721

Experimental Data Snapshot

  • Resolution: 1.77 Å
  • R-Value Free: 0.208 
  • R-Value Work: 0.173 
  • R-Value Observed: 0.173 

wwPDB Validation   3D Report Full Report

Ligand Structure Quality Assessment 

This is version 1.2 of the entry. See complete history


The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central A beta Pharmacodynamic Responses in Mice, Dogs, and Humans.

May, P.C.Willis, B.A.Lowe, S.L.Dean, R.A.Monk, S.A.Cocke, P.J.Audia, J.E.Boggs, L.N.Borders, A.R.Brier, R.A.Calligaro, D.O.Day, T.A.Ereshefsky, L.Erickson, J.A.Gevorkyan, H.Gonzales, C.R.James, D.E.Jhee, S.S.Komjathy, S.F.Li, L.Lindstrom, T.D.Mathes, B.M.Martenyi, F.Sheehan, S.M.Stout, S.L.Timm, D.E.Vaught, G.M.Watson, B.M.Winneroski, L.L.Yang, Z.Mergott, D.J.

(2015) J Neurosci 35: 1199-1210

  • DOI: https://doi.org/10.1523/JNEUROSCI.4129-14.2015
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 

    BACE1 is a key protease controlling the formation of amyloid β, a peptide hypothesized to play a significant role in the pathogenesis of Alzheimer's disease (AD). Therefore, the development of potent and selective inhibitors of BACE1 has been a focus of many drug discovery efforts in academia and industry. Herein, we report the nonclinical and early clinical development of LY2886721, a BACE1 active site inhibitor that reached phase 2 clinical trials in AD. LY2886721 has high selectivity against key off-target proteases, which efficiently translates in vitro activity into robust in vivo amyloid β lowering in nonclinical animal models. Similar potent and persistent amyloid β lowering was observed in plasma and lumbar CSF when single and multiple doses of LY2886721 were administered to healthy human subjects. Collectively, these data add support for BACE1 inhibition as an effective means of amyloid lowering and as an attractive target for potential disease modification therapy in AD.

  • Organizational Affiliation

    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285.

Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Beta-secretase 1
A, B
442Homo sapiensMutation(s): 0 
Gene Names: BACE1BACEKIAA1149
UniProt & NIH Common Fund Data Resources
Find proteins for P56817 (Homo sapiens)
Explore P56817 
Go to UniProtKB:  P56817
PHAROS:  P56817
GTEx:  ENSG00000186318 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP56817
Sequence Annotations
  • Reference Sequence
Small Molecules
Binding Affinity Annotations 
IDSourceBinding Affinity
3YS BindingDB:  4X7I IC50: min: 12, max: 20 (nM) from 2 assay(s)
Experimental Data & Validation

Experimental Data

  • Resolution: 1.77 Å
  • R-Value Free: 0.208 
  • R-Value Work: 0.173 
  • R-Value Observed: 0.173 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 86.432α = 90
b = 89.773β = 90
c = 130.663γ = 90
Software Package:
Software NamePurpose
SCALAdata scaling

Structure Validation

View Full Validation Report

Ligand Structure Quality Assessment 

Entry History 

Deposition Data

  • Released Date: 2014-12-24 
  • Deposition Author(s): Timm, D.E.

Revision History  (Full details and data files)

  • Version 1.0: 2014-12-24
    Type: Initial release
  • Version 1.1: 2015-02-04
    Changes: Database references
  • Version 1.2: 2017-11-22
    Changes: Derived calculations, Refinement description, Source and taxonomy